Literature DB >> 17005457

Inhibition of glutaminyl cyclase alters pyroglutamate formation in mammalian cells.

Holger Cynis1, Stephan Schilling, Mandy Bodnár, Torsten Hoffmann, Ulrich Heiser, Takaomi C Saido, Hans-Ulrich Demuth.   

Abstract

Mammalian cell lines were examined concerning their Glutaminyl Cyclase (QC) activity using a HPLC method. The enzyme activity was suppressed by a QC specific inhibitor in all homogenates. Aim of the study was to prove whether inhibition of QC modifies the posttranslational maturation of N-glutamine and N-glutamate peptide substrates. Therefore, the impact of QC-inhibition on amino-terminal pyroglutamate (pGlu) formation of the modified amyloid peptides Abeta(N3E-42) and Abeta(N3Q-42) was investigated. These amyloid-beta peptides were expressed as fusion proteins with either the pre-pro sequence of TRH, to be released by a prohormone convertase, or as engineered amyloid precursor protein for subsequent liberation of Abeta(N3Q-42) after beta- and gamma-secretase cleavage during posttranslational processing. Inhibition of QC leads in both expression systems to significantly reduced pGlu-formation of differently processed Abeta-peptides. This reveals the importance of QC-activity during cellular maturation of pGlu-containing peptides. Thus, QC-inhibition should impact bioactivity, stability or even toxicity of pyroglutamyl peptides preventing glutamine and glutamate cyclization.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17005457     DOI: 10.1016/j.bbapap.2006.08.003

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  24 in total

1.  Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease.

Authors:  Jessica L Wittnam; Erik Portelius; Henrik Zetterberg; Mikael K Gustavsson; Stephan Schilling; Birgit Koch; Hans-Ulrich Demuth; Kaj Blennow; Oliver Wirths; Thomas A Bayer
Journal:  J Biol Chem       Date:  2012-01-20       Impact factor: 5.157

2.  Amyloid-β Peptide Aβ3pE-42 Induces Lipid Peroxidation, Membrane Permeabilization, and Calcium Influx in Neurons.

Authors:  Adam P Gunn; Bruce X Wong; Timothy Johanssen; James C Griffith; Colin L Masters; Ashley I Bush; Kevin J Barnham; James A Duce; Robert A Cherny
Journal:  J Biol Chem       Date:  2015-12-23       Impact factor: 5.157

Review 3.  Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer disease.

Authors:  Sadim Jawhar; Oliver Wirths; Thomas A Bayer
Journal:  J Biol Chem       Date:  2011-09-29       Impact factor: 5.157

4.  Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate A{beta} formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice.

Authors:  Sadim Jawhar; Oliver Wirths; Stephan Schilling; Sigrid Graubner; Hans-Ulrich Demuth; Thomas A Bayer
Journal:  J Biol Chem       Date:  2010-12-10       Impact factor: 5.157

5.  Distinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Abeta pathology in Alzheimer's disease.

Authors:  Markus Morawski; Maike Hartlage-Rübsamen; Carsten Jäger; Alexander Waniek; Stephan Schilling; Claudia Schwab; Patrick L McGeer; Thomas Arendt; Hans-Ulrich Demuth; Steffen Rossner
Journal:  Acta Neuropathol       Date:  2010-04-10       Impact factor: 17.088

Review 6.  Alternative pathways for production of beta-amyloid peptides of Alzheimer's disease.

Authors:  Vivian Hook; Israel Schechter; Hans-Ulrich Demuth; Gregory Hook
Journal:  Biol Chem       Date:  2008-08       Impact factor: 3.915

7.  Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms.

Authors:  Maike Hartlage-Rübsamen; Markus Morawski; Alexander Waniek; Carsten Jäger; Ulrike Zeitschel; Birgit Koch; Holger Cynis; Stephan Schilling; Reinhard Schliebs; Hans-Ulrich Demuth; Steffen Rossner
Journal:  Acta Neuropathol       Date:  2011-02-08       Impact factor: 17.088

8.  Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases.

Authors:  Oliver Wirths; Tobias Bethge; Andrea Marcello; Anja Harmeier; Sadim Jawhar; Paul J Lucassen; Gerd Multhaup; David L Brody; Thomas Esparza; Martin Ingelsson; Hannu Kalimo; Lars Lannfelt; Thomas A Bayer
Journal:  J Neural Transm (Vienna)       Date:  2009-10-13       Impact factor: 3.575

9.  Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model.

Authors:  Oliver Wirths; Henning Breyhan; Holger Cynis; Stephan Schilling; Hans-Ulrich Demuth; Thomas A Bayer
Journal:  Acta Neuropathol       Date:  2009-06-23       Impact factor: 17.088

Review 10.  APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesis.

Authors:  Leslie Crews; Edward Rockenstein; Eliezer Masliah
Journal:  Brain Struct Funct       Date:  2009-11-29       Impact factor: 3.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.